Back to results
US 2022/0016166 A1Published application
T-cell expressing chimeric receptor
AssigneeCafa Therapeutics Limited
InventorsZonghai LI, Zhaohui LIAO
Life of this patent
Estimating the term…
Abstract
Provided is a T-cell expressing a chimeric receptor, wherein the chimeric receptor specifically recognizes BCMA, and the endogenous TCR molecule and the endogenous MHC molecule are silenced. Also provided is the use of the T-cell in the preparation of a drug for treating BCMA positive tumors.
Claims24
1-22. (canceled)
A T cell expressing a chimeric receptor that specifically recognizes BCMA, wherein the endogenous TCR molecule is silenced and the endogenous MHC molecule is silenced in the T cell.
Dependencies are inferred from the claim text.